Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
Most Recent Events
- 30 Jan 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2030.
- 30 Jan 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2030.
- 30 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2028.